Introducing the Adcendo Leadership Team
Adcendo’s leadership team has a proven track record in ADC development, having played a direct role in the discovery, development and approval of multiple marketed ADC therapies, including Trodelvy®, Enhertu®, Tivdak®. With our deep expertise spanning preclinical and clinical development, regulatory strategy, CMC, and commercialization, our team combines cutting-edge biotech innovation with the operational excellence of leading global pharma.
Michael Pehl, MSc
Chief Executive Officer
Michael serves as our Chief Executive Officer and a Board Director. Michael brings ample leadership experience from global pharmaceutical and biotechnology companies, having led multiple marketed hematology & oncology products through development and commercialization, including Revlimid®, Vidaza®, Trodelvy®, Abraxane® and Reblozyl®. Among his many roles, Michael served as Chief Executive Officer of Immunomedics, Inc. and President of Hematology & Oncology of Celgene Corporation.
Lone H. Ottesen, MD, PhD
Chief Medical Officer
Lone serves as our Chief Medical Officer, bringing extensive expertise in global drug development across antibody-drug conjugates (ADCs), immune therapies and small molecules, from first-in-human studies to global registration-directed trials. Prior to joining Adcendo, Lone led several Global Clinical Development teams at AstraZeneca PLC, Early Oncology Development at Eisai Inc., and held key medical leadership roles at GlaxoSmithKline Oncology.
Fang Z. Ni, Pharm.D.
Chief Financial Officer
Fang Ni serves as our Chief Financial Officer and leads our operations in the United States. He brings a strong track record in executive leadership, corporate development, financial strategy and growth. Before joining Adcendo, Fang served as Chief Financial Officer and Chief Business Officer at Black Diamond Therapeutics. He also held the role of Chief Business Officer at Monte Rosa Therapeutics and drove strategic growth at several other innovative biotech startups. Fang previously worked as a Principal at Versant Ventures supporting biotech investments and held corporate development roles at Roche Pharmaceuticals across its U.S. and Swiss operations.
Dominik Mumberg, PhD
Chief Scientific Officer
Dominik serves as our Chief Scientific Officer, overseeing the company’s research and nonclinical development activities from target selection through pharmacology and IND-enabling studies. Prior to joining Adcendo, Dominik served in multiple leadership roles at Schering AG and Bayer AG, including VP of Oncology Research and Translational Innovation Lead. Under Dominik’s leadership, numerous programs advanced from research into clinical development, including ADCs, radio-immunoconjugates, and targeted therapies.
Pernille Hemmingsen, PhD
Chief Technology Officer
Pernille serves as our Chief Technology Officer and is responsible for CMC and global supply at Adcendo. Pernille brings over 20 years of technical operations experience in the pharmaceutical industry. Prior to joining Adcendo, Pernille served as VP of Global Product Development and Supply at Savara ApS, as well as led the Tivdak® CMC program from non-clinical through late-stage development at Genmab A/S.
James Wang, PhD
VP, Head of Business Development
James serves as our VP, Head of Business Development and is responsible for alliance management, competitive intelligence, and intellectual property at Adcendo. Prior to joining Adcendo, James served as Senior Director of Business Development at Innovent Biologics Inc, and Simcere Pharmaceuticals Group, leading numerous strategic licensing deals for assets and technologies, including ADCs. Earlier in his career, James served as Associate Director, Global Product & Portfolio Strategy at AstraZeneca PLC
Margaret McNaull, BSc, MBA
VP, Head of Clinical Operations
Margaret serves as our VP, Head of Clinical Operations, bringing global development expertise spanning ADCs, immune therapies, small molecules as well as biosimilars, spanning early development to post-commercialization. Prior to joining Adcendo, Margaret was head of Project Management Centre of Excellence at AstraZeneca PLC and led clinical operations across multiple late-stage development programs through regulatory submission and approval.
Victoria Marsh, PhD
VP, Head of Regulatory and Safety
Victoria (Vic) serves as our VP, Head of Regulatory and Safety, driving regulatory strategies and ensuring the safety and compliance of products across the Adcendo portfolio. Vic brings a proven track record of global regulatory leadership for a range of ADCs, biologics, and small molecule drugs spanning their full product lifecycle. Prior to joining Adcendo, Vic served as Executive Director at AVROBIO Inc, Senior Director at AstraZeneca PLC, and consultant to several biotech companies.
Lars Dreiøe, MSc, Exec MBA
VP, Head of Quality Assurance
Lars serves as our VP Head of Quality Assurance and oversees quality in all regulated activities at Adcendo. Prior to joining Adcendo, Lars served in multiple senior leadership positions including Head of Quality at ALK A/S, Sobi AB and Genmab A/S and holds extensive compliance experience from successfully bringing novel treatments to the market within endocrinology, haemophilia and oncology.
Jared Lurk, PharmD
VP, Medical Affairs, US
Jared is the Vice President and Head of U.S. Medical Affairs at Adcendo, where he leverages a proven history of engaging with key opinion leaders, driving clinical development, and applying his extensive scientific expertise. Prior to joining Adcendo, Jared served as Senior Director of Research Services for Pfizer Oncology. In this role, he led field medical teams in fostering partnerships with opinion leaders and overseeing their involvement in company-sponsored research initiatives.
Mikkel Krogh-Madsen, PhD
VP, Head of Portfolio & Program Management
Mikkel serves as our VP, Head of Portfolio & Program Management, leading the project management organization and portfolio strategy at Adcendo. Prior to joining Adcendo, Mikkel served as Global Project Leader & Director at LEO Pharma A/S and was responsible for global R&D strategy across phases of clinical development for biologics products such as Kyntheum® and temtokibart. In addition, Mikkel also served on the Strategic Development Leadership Team at LEO Pharma
Serafino Pantano, PhD
VP, Head of Translational Medicine and Diagnostics